Cytomegalovirus (CMV) infection – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Cytomegalovirus (CMV) is a ubiquitous virus that infects the majority of humans of all ages. CMV is a member of the herpes virus family which includes the herpes simplex viruses and the viruses that cause chickenpox and mononucleosis. Human cytomegalovirus (HCMV) is a species of the Cytomegalovirus genus of viruses, of the viral family Herpes viridae or herpes viruses, and is the most common of all cytomegaloviruses. The primary infection manifests as an asymptomatic or self-limited febrile illness in immuno-competent individuals, after which CMV establishes life-long latency in various cells which serve as reservoirs for reactivation and as carriers of infection to susceptible individuals. The method of spread of this infection varies. Direct contact with body fluids from an infected person exposes an individual to CMV. Most healthy children and adults do not experience any symptoms after infection with CMV. However, CMV may cause serious disease in people with a weakened immune system (such as those with HIV/AIDS or those taking medications that suppress immunity). CMV can cause retinitis (blurred vision and blindness), painful swallowing (dysphagia), pneumonia, diarrhea (colitis), and weakness or numbness in the legs.

 

The incidence of CMV infection is found out to be 35% in allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients. However, within the transplant patients, 34% to 40% of patients developed at least one CMV episode at 12 months and 88% of patients develop at least one CMV episode within 6 months.

 

The competitive landscape of Cytomegalovirus (CMV) infection includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Cytomegalovirus (CMV) infection across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cytomegalovirus (CMV) infection Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Cytomegalovirus (CMV) infection – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Maribavir          Takeda Pharmaceutical Phase 3

2          MCMV3068A    Genentech, Inc. Phase 2

3          NPC-21 Nobelpharma    Phase 2

4          Brincidofovir      Chimerix           Phase 3

5          Pentamer          GlaxoSmithKline            Phase 1/2

6          Letermovir        Merck Sharp & Dohme Corp.     Phase 2

7          mRNA-1647      ModernaTX, Inc.           Phase 3

8          VBI-1501A        VBI Vaccines Inc.          Phase 1

9          Viralym-C          AlloVir   Phase 2

10        ASP0113          Astellas Pharma Global Development, Inc.            Phase 1

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more